Results 61 to 70 of about 13,960 (212)

Type‐2‐Inflammatory‐Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

open access: yesAllergy, EarlyView.
Studies suggest that type 2 inflammatory diseases are driven by overactivation of the IL4/IL13 pathway, manifesting differently in distinct tissues. We performed quantitative analyses using several large independent datasets to explore the interrelation of type 2 inflammatory diseases based on co‐prevalence, genetic predispositions, and transcriptomic ...
Jennifer D. Hamilton   +19 more
wiley   +1 more source

Early Intervention With Biologics for Asthma Remission: Promising or Premature?

open access: yes
Respirology, EarlyView.
Santi Nolasco   +2 more
wiley   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

open access: yesAllergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin   +4 more
wiley   +1 more source

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma

open access: yesAllergy, EarlyView.
EXPEDITION (NCT02573233) assessed the effects of dupilumab on airway inflammation in patients with persistent asthma using bronchoscopy and gene expression analysis. Dupilumab showed no appreciable effect on inflammatory cell types in biopsies or BALF samples.
Michael E. Wechsler   +22 more
wiley   +1 more source

[Exhaled nitric oxide of childhood asthma].

open access: yesArerugi = [Allergy], 1999
Chronic airway inflammation is a central feature of pathology of bronchial asthma. In order to evaluate inflammatory status in asthma, examinations such as bronchoscope or induced sputum test can be done. Because of difficulty of those examinations we need non-invasive and simple measures for childhood asthma.
Terada, Akihiko   +4 more
openaire   +2 more sources

Natural History of Alternaria Sensitisation and Association With Asthma and Rhinitis From Childhood to Adulthood

open access: yesAllergy, EarlyView.
We aimed to characterise Alternaria sensitisation trajectories from childhood to adulthood; we compared SPT, whole‐extract sIgE and rAlt a 1, and assessed their longitudinal association with asthma and rhinitis in the Isle of Wight birth cohort. Alternaria sensitisation in the Isle of Wight Birth Cohort emerges mainly in late adolescence and, when ...
Mohammad Leily   +7 more
wiley   +1 more source

Reference values for exhaled nitric oxide (reveno) study

open access: yesRespiratory Research, 2006
Background Despite the widespread use of fractional exhaled nitric oxide (FENO) as a biomarker of airways inflammation, there are no published papers describing normal FENO values in a large group of healthy adults. Objective The aim of this study was to
Mutti Antonio   +6 more
doaj   +1 more source

Serotonin Degradation and Lipid Metabolism Regulate Human Tc2 Cell Effector Functions

open access: yesAllergy, EarlyView.
Human Tc2 cells exhibit a metabolically active phenotype characterized by enhanced glycolysis, mitochondrial respiration, and fatty acid uptake dependent on PPARγ. Alarmins strongly amplify IL‐5 and IL‐13 production in Tc2 cells, supporting a shared immunometabolic program across type 2 lymphocytes.
Sabrina de Souza Ferreira   +13 more
wiley   +1 more source

Exhaled nitric oxide - circadian variations in healthy subjects

open access: yesEuropean Journal of Medical Research, 2009
Objective Exhaled nitric oxide (eNO) has been suggested as a marker of airway inflammatory diseases. The level of eNO is influenced by many various factor including age, sex, menstrual cycle, exercise, food, drugs, etc.
Antosova M   +4 more
doaj   +1 more source

Remission in Global Airway Diseases: EUFOREA Consensus Paper

open access: yesAllergy, EarlyView.
ABSTRACT The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission. Disease‐modifying therapies, including biologics and allergen immunotherapy, have made remission achievable in patients with severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), or allergic rhinitis (AR).
J. Christian Virchow   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy